Octec 0.5 Drug Interactions

Avoid concomitant use of Fingolimod with: Bretylium may result in increased risk of bradycardia or heart block.
Avoid concomitant use of Fingolimod with: Levomethadyl may result in increased risk of QT interval prolongation and Torsade de Pointes.
Avoid concomitant use of Fingolimod with: Dofetilide, amiodarone, ibutilide, disopyramide, quinidine, procainamide, sotalol may result in increased risk of QT interval prolongation, bradycardia, or heart block. 
Avoid concomitant use of Fingolimod with: Mesoridazine, ziprasidone, saquinavir, sparfloxacin, bepridil, piperaquine, terfenadine, thioridazine, pimozide, dronedarone, cisapride and other QT prolonging drugs may result in increased risk of QT-interval prolongation.
Fingolimod may increase the levels/effects of: Antiarrhythmic agents (class la); Antiarrhythmic agents (class III); Bradycardia-causing agents; ceretinib; Higher risk QTc prolonging agents; ivabradine; lacosamide; leflunomide; Moderate risk QTc-prolonging agents; natalizumab; tofacitinib; Vaccines (live); zoster vaccine.
The levels/effects of Fingolimod may be increased by: Beta-blockers; bretylium; denosumab; diltiazem; esmolol; Immunosuppressants; ketoconazole (systemic); mifepristone; pimecrolimus; roflumilast; tacrolimus (topical); trastuzumab; verapamil.
Fingolimod may decrease the levels/effects of: BCG (intravesical); Coccidioides immitis skin test; nivolumab; Sipuleucel-T; Vaccines (inactivated); Vaccines (live); zoster vaccine.
The levels/effects of Fingolimod may be decreased by: Carbamazepine; echinacea.